Yes, targeting NHEJ has therapeutic potential. Inhibitors of DNA-PKcs, such as NU7441 and M3814, are being explored to enhance the efficacy of radiotherapy and chemotherapy. Additionally, combining NHEJ inhibitors with other treatments, like PARP inhibitors, can exploit synthetic lethality in tumors with defective homologous recombination, such as BRCA1/2-mutated cancers.
